The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Review Article
Mechanisms of Disease
PreviousPrevious
Volume 330:613-622 March 3, 1994 Number 9
NextNext

Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Stuart A. Lipton, and Paul A. Rosenberg

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
In many neurologic disorders, injury to neurons may be caused at least in part by overstimulation of receptors for excitatory amino acids, including glutamate and aspartate. These neurologic conditions range from acute insults such as stroke, hypoglycemia, trauma, and epilepsy (Table 1) to chronic neurodegenerative states such as Huntington's disease, the acquired immunodeficiency syndrome (AIDS) dementia complex, amyotrophic lateral sclerosis, and perhaps Alzheimer's disease (Table 2)1,2,3.

View this table:
[in this window]
[in a new window]
 
Table 1. Acute Neurologic Disorders Thought to Be Mediated at Least in Part through Stimulation of Glutamate Receptors.

 
View this table:
[in this window]
[in a new window]
 
Table 2. Chronic Neurodegenerative Diseases Thought to Be Mediated at Least in Part through Stimulation . . . [Full Text of this Article]

 
Types of Excitatory Amino Acid Receptors

Intracellular Calcium and Neurotoxicity

Pathogenesis of Excitotoxicity

Mechanisms of Abnormal Glutamate Accumulation

            Glutamate Transport

            Release of Glutamate from Vesicular Stores

            Injury and Glutamate Release

            Role of Energy Failure in Neuronal Injury

Pathophysiology of Excitotoxicity at the Receptor Level

Potentiation of Postsynaptic Glutamate Responses

Pharmacotherapy for Excitatory Amino Acid-Induced Neurologic Disorders

Possible Sites of Action

NMDA Open-Channel Blockers

NMDA Redox Modulatory Site

Drugs Recently Approved and Clinical Trials in Progress

Conclusions


Source Information

From the Harvard-Longwood Neurology Program and the Laboratory of Cellular and Molecular Neuroscience, Department of Neurology, Children's Hospital (S.A.L., P.A.R.); the Departments of Neurology, Beth Israel Hospital, Brigham and Women's Hospital, and Massachusetts General Hospital (S.A.L.); and Harvard Medical School (S.A.L., P.A.R.) -- all in Boston.

Address reprint requests to Dr. Lipton at the Harvard-Longwood Neurology Program, 300 Longwood Ave., Enders Bldg., Suite 361, Boston, MA 02115.

References


Related Letters:

Excitatory Amino Acids in Neurologic Disorders
Samuels A., Seifter S., Lipton S. A., Rosenberg P. A.
Extract | Full Text  
N Engl J Med 1994; 331:274-275, Jul 28, 1994. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.